GlaxoSmithKline Submits BLA for Cervarix HPV Vaccine
GlaxoSmithKline Submits BLA for Cervarix HPV Vaccine
PHILADELPHIA, PennsylvaniaGlaxoSmithKline has submitted to the FDA a Biologics License Application (BLA) for Cervarix (human papillomavirus vaccine, AS04 adjuvant-adsorbed), its cervical cancer candidate vaccine. The vaccine is formulated with a proprietary adjuvant system called AS04 containing aluminum hydroxide and monophosphoryl lipid A. The submission includes data from clinical trials in almost 30,000 females age 10 to 55 reflecting an ethnically diverse population, the company said.
Articles in this issue
Curcumin Evaluated for the Treatment of Pancreatic Cancer
Tykerb Approved for Metastatic HER2+ Breast Cancer
'Male Lumpectomy' Via Focal Cryoablation Expands Treatment Options for Selected Prostate Cancer Patients
Drug for BPH May Also Reduce the Risk of Prostate Cancer
Phase III Trial of Prostvac-VF Is Launched
Electronic System Reminds Patients to Schedule Exams
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Related Content
!["[The Teal Wand] offers an evidence-based way to expand access [to screening] without compromising accuracy,” according to Christine Conageski, MD, MSc, from the University of Colorado Anschutz Medical Campus.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fc41c601528cfbdb8b14b609e326649f33f596c38-1200x675.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"[The Teal Wand] offers an evidence-based way to expand access [to screening] without compromising accuracy,” according to Christine Conageski, MD, MSc, from the University of Colorado Anschutz Medical Campus.")
